Study Summary
This trial proposes using a non-invasive technology to modulate brain circuits in order to reduce tics in Tourette Syndrome patients.
- Tourette Syndrome
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: On the same day, we will assess change in cSP prior to active (or sham) iTBS treatment and immediately after iTBS treatment
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
iTBS
1 of 2
Sham iTBS
1 of 2
Experimental Treatment
Non-Treatment Group
30 Total Participants · 2 Treatment Groups
Primary Treatment: iTBS · Has Placebo Group · Phase < 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 10 - 21 · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Is registration for this clinical trial still available?
"Affirmative, clinicaltrials.gov's records demonstrate that this medical trial is actively recruiting patients as of now. This study was initially posted on November 1st 2022 and its latest edition occurred on November 23rd 2022. The research requires 30 participants to be enrolled at a single site." - Anonymous Online Contributor
Is this clinical trial open to all individuals, or are there certain eligibility criteria?
"Applicants for this trial must be between 10 and 21 years old with a diagnosis of gilles de la tourette syndrome. A total of 30 candidates are being sought after to participate in the study." - Anonymous Online Contributor
What is the aggregate enrollment for this scientific investigation?
"Indeed, the information on clinicaltrials.gov affirms that this trial is in search of volunteers. The study was initially published on November 1st 2022 and has been recently updated as of November 23rd 2022. This examination requires 30 participants at one site to begin." - Anonymous Online Contributor
Does this research incorporate individuals who are elderly?
"Patients who meet the trial's inclusion criteria must be between 10 and 21 years old. Notably, there are 382 trials recruiting patients under 18 while 990 recruit those over 65." - Anonymous Online Contributor